Interferon in the Treatment of Cutaneous T-Cell Lymphoma

The document from December 2003 examines the effectiveness of interferon (IFN), particularly alfa interferon (IFN-α), in treating cutaneous T-cell lymphoma (CTCL). It reports that IFN-α as a single agent achieved over 50% partial remission and over 20% complete responses, with side effects that were predictable and generally well tolerated. The response to IFN-α did not significantly differ between early and advanced stages of CTCL, although patients with tumor-stage CTCL of large cell histology responded poorly. The presence of neutralizing antibodies to IFN could affect treatment response but was not always detrimental and could be reversible. Combination therapies, including IFN with PUVA and other agents, showed high response rates and potential synergistic effects. The document also discusses beta interferons and interferon gamma (IFN-γ), noting similar side effects to IFN-α and an objective response in 31% of patients treated with IFN-γ. Overall, IFN, especially IFN-α, was found to be a potent treatment for CTCL, with combination therapies offering additional benefits. Side effects were typically dose-related and could improve over time or with dose reduction.